Showing results (31-40 of 56) with videos related to
Sort By:
Pageof 6
Proceedings of the National Academy of Sciences of the United States of America|April 13, 2011
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cellsChristy C Ong, Adrian M Jubb, Peter M Haverty, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2009
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer modelsKlaus P Hoeflich, Carol O'Brien, Zachary Boyd, et al.Cancer Research|November 10, 2012
An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancerMark L McCleland, Adam S Adler, Yonglei Shang, et al.Nature Communications|February 22, 2017
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in miceJanet Lau, Jeanne Cheung, Armando Navarro, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2012
Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitorHarvey Wong, Laurent Vernillet, Amy Peterson, et al.Plos One|May 10, 2012
Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodesJeffrey J Wallin, Jane Guan, Kyle A Edgar, et al.Journal of the National Cancer Institute|March 29, 2013
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanomaChristy C Ong, Adrian M Jubb, Diana Jakubiak, et al.Cancer Research|September 16, 2022
A Probody T Cell-Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited ToxicityLeila M Boustany, Sherry L LaPorte, Laurie Wong, et al.Molecular Cancer Therapeutics|March 10, 2012
ERK inhibition overcomes acquired resistance to MEK inhibitorsGeorgia Hatzivassiliou, Bonnie Liu, Carol O'Brien, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2013
Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor modelsJie Lin, Deepak Sampath, Michelle A Nannini, et al.Pageof 6